Extended Data Fig. 6: On-chip response curves under treatment of different patient derived 2nd-gen CAR T cells.
(a) Schematic of on-chip evaluation of patient derived CAR T cell products. Created in BioRender. MA, C. (2025) https://BioRender.com/04m813s. (b) Manufacturing of patient derived CAR T cells, where three patients with B-ALL leukaemia (PD323, PD356, and PD674) and one control patient with lung cancer (PD145). (c) On-chip response curves under treatment of different patient derived CAR T cells, PD145 CAR, PD323 CAR, PD356 CAR, and PD674 CAR (ProMab) at a dose of 10,000 T cells. Data was collected from three technical replicates (n = 3). (d) Surface expression of CD25 on patient derived CAR T cells, PD145 CAR, PD323 CAR, PD356 CAR, and PD674 CAR, after on-chip interaction for 2 days. Data was collected from at least three technical replicates (n = 3). One-way ANOVA followed by Kruskal-Wallis’ test, mean and s.e.m. (e) Cytokine secretion profiles of patient-derived CAR T cell products, PD145 CAR, PD323 CAR, PD356 CAR, and PD674 CAR, on-chip at day 2 were examined by using a Human Inflammation Array C3 membrane kit. Data was collected from two independent experiments (n = 2). (f) Radar map depicting functional performance, that is, activation, effector, stimulator, chemoattractive, proinflammatory, and regulatory, of different PD CAR T cells. PD145 CAR outperformed other PD CAR T cell products.
